MedTrace Logo

The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder

NCT02344784 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2016-08-23

No results posted yet for this study

Summary

The purpose of this study is to show that Prepulse inhibition test of acoustic startle response is an indicator of objective diagnostic characteristics of attention deficit disorder in children and adolescents.

by demonstrating that Prepulse inhibition test of acoustic startle response is impaired in children and adolescents suffering from attention deficit disorder in the relation to the normal function described in the literature.

The investigators will try to prove our hypothesis by an experiment that consists of two phases:

Phase I (about 25 minutes):

The patient will enter the room, will be asked to sit on a chair, and will be asked to look at a computer screen showing silent video of aquarium fish, then the patient will be connected to both the Prepulse inhibition test device and the Galvanic skin response device and pass the tests.

Phase II (about 25 minutes):

After completion of Phase I, each participant will receive his daily regular dose of methylphenidate and after an hour and a half from taking the drug, will repeat the tests, both the Prepulse inhibition test and the Galvanic skin response test.

Duration of the entire experiment is 140 minutes (two hours and twenty minutes).

Conditions

  • Attention Deficit Disorder

Interventions

DEVICE

SR-HLAB EMG

Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment

DRUG

Methylphenidate

The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    collaborator OTHER

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • AVRAHAM AVITAL · Technion, Israel Institute of Technology

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-03-31
Completion
2017-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02344784 on ClinicalTrials.gov